NASDAQ:INGN

Inogen Competitors

$50.36

-2.78 (-5.23 %)

(As of 03/2/2021 12:30 PM ET)

Add

Compare

Today's Range

$50.24

Now: $50.36▼

$52.15

50-Day Range

$43.97

MA: $50.48▼

$55.99

52-Week Range

$26.57

Now: $50.36▼

$56.46

Volume2,937 shs

Average Volume167,099 shs

Market Capitalization$1.12 billion

P/E RatioN/A

Dividend YieldN/A

Beta1.05

Inogen (NASDAQ:INGN) Vs. AVNS, EAR, ESTA, SIEN, IVC, and LAKE

Should you be buying INGN stock or one of its competitors? Companies in the industry of "surgical appliances & supplies" are considered alternatives and competitors to Inogen, including Avanos Medical (AVNS), Eargo (EAR), Establishment Labs (ESTA), Sientra (SIEN), Invacare (IVC), and Lakeland Industries (LAKE).

Inogen vs. Avanos Medical Stock

Inogen (NASDAQ:INGN) and Avanos Medical (NYSE:AVNS) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation and earnings.

Risk and Volatility

Inogen has a beta of 1.05, indicating that its share price is 5% more volatile than the S&P 500. Comparatively, Avanos Medical has a beta of 1.12, indicating that its share price is 12% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Inogen and Avanos Medical, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inogen	0	3	1	0	2.25
Avanos Medical	1	2	2	0	2.20

Inogen currently has a consensus target price of $63.00, indicating a potential upside of 22.35%. Avanos Medical has a consensus target price of $38.40, indicating a potential downside of 15.92%. Given Inogen's stronger consensus rating and higher probable upside, research analysts plainly believe Inogen is more favorable than Avanos Medical.

Institutional & Insider Ownership

95.1% of Inogen shares are owned by institutional investors. Comparatively, 94.8% of Avanos Medical shares are owned by institutional investors. 4.8% of Inogen shares are owned by insiders. Comparatively, 1.5% of Avanos Medical shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Inogen and Avanos Medical's revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inogen	$361.94 million	3.10	$20.95 million	$1.07	47.07
Avanos Medical	$697.60 million	3.14	$-45,900,000.00	$1.07	42.76

Inogen has higher earnings, but lower revenue than Avanos Medical. Avanos Medical is trading at a lower price-to-earnings ratio than Inogen, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Inogen and Avanos Medical's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Inogen	-0.66%	0.21%	0.16%
Avanos Medical	1.93%	3.20%	2.28%

Summary

Avanos Medical beats Inogen on 8 of the 13 factors compared between the two stocks.

Inogen vs. Eargo Stock

Eargo (NASDAQ:EAR) and Inogen (NASDAQ:INGN) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, risk, institutional ownership, dividends and valuation.

Insider and Institutional Ownership

95.1% of Inogen shares are owned by institutional investors. 4.8% of Inogen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Eargo and Inogen's gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eargo	N/A	N/A	N/A	N/A	N/A
Inogen	$361.94 million	3.10	$20.95 million	$1.07	47.07

Inogen has higher revenue and earnings than Eargo.

Analyst Ratings

This is a summary of current ratings for Eargo and Inogen, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eargo	0	0	4	0	3.00
Inogen	0	3	1	0	2.25

Eargo currently has a consensus price target of $48.00, indicating a potential downside of 17.06%. Inogen has a consensus price target of $63.00, indicating a potential upside of 22.35%. Given Inogen's higher possible upside, analysts clearly believe Inogen is more favorable than Eargo.

Profitability

This table compares Eargo and Inogen's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Eargo	N/A	N/A	N/A
Inogen	-0.66%	0.21%	0.16%

Summary

Inogen beats Eargo on 6 of the 9 factors compared between the two stocks.

Inogen vs. Establishment Labs Stock

Establishment Labs (NASDAQ:ESTA) and Inogen (NASDAQ:INGN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations and profitability.

Risk & Volatility

Establishment Labs has a beta of 1.15, indicating that its stock price is 15% more volatile than the S&P 500. Comparatively, Inogen has a beta of 1.05, indicating that its stock price is 5% more volatile than the S&P 500.

Earnings & Valuation

This table compares Establishment Labs and Inogen's revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Establishment Labs	$89.57 million	17.82	$-38,150,000.00	($1.86)	-36.62
Inogen	$361.94 million	3.10	$20.95 million	$1.07	47.07

Inogen has higher revenue and earnings than Establishment Labs. Establishment Labs is trading at a lower price-to-earnings ratio than Inogen, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Establishment Labs and Inogen's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Establishment Labs	-46.40%	-49.51%	-24.21%
Inogen	-0.66%	0.21%	0.16%

Insider & Institutional Ownership

54.8% of Establishment Labs shares are owned by institutional investors. Comparatively, 95.1% of Inogen shares are owned by institutional investors. 2.6% of Establishment Labs shares are owned by company insiders. Comparatively, 4.8% of Inogen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations for Establishment Labs and Inogen, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Establishment Labs	0	1	4	0	2.80
Inogen	0	3	1	0	2.25

Establishment Labs currently has a consensus target price of $41.40, suggesting a potential downside of 39.22%. Inogen has a consensus target price of $63.00, suggesting a potential upside of 22.35%. Given Inogen's higher probable upside, analysts clearly believe Inogen is more favorable than Establishment Labs.

Summary

Inogen beats Establishment Labs on 9 of the 14 factors compared between the two stocks.

Inogen vs. Sientra Stock

Sientra (NASDAQ:SIEN) and Inogen (NASDAQ:INGN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends and earnings.

Profitability

This table compares Sientra and Inogen's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sientra	-123.88%	-174.05%	-38.97%
Inogen	-0.66%	0.21%	0.16%

Risk and Volatility

Sientra has a beta of 1.81, meaning that its share price is 81% more volatile than the S&P 500. Comparatively, Inogen has a beta of 1.05, meaning that its share price is 5% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Sientra and Inogen, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sientra	0	0	6	0	3.00
Inogen	0	3	1	0	2.25

Sientra currently has a consensus target price of $8.20, suggesting a potential upside of 4.73%. Inogen has a consensus target price of $63.00, suggesting a potential upside of 22.35%. Given Inogen's higher possible upside, analysts plainly believe Inogen is more favorable than Sientra.

Earnings and Valuation

This table compares Sientra and Inogen's gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sientra	$83.70 million	4.73	$-106,820,000.00	($2.29)	-3.42
Inogen	$361.94 million	3.10	$20.95 million	$1.07	47.07

Inogen has higher revenue and earnings than Sientra. Sientra is trading at a lower price-to-earnings ratio than Inogen, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

71.0% of Sientra shares are owned by institutional investors. Comparatively, 95.1% of Inogen shares are owned by institutional investors. 2.8% of Sientra shares are owned by company insiders. Comparatively, 4.8% of Inogen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Inogen beats Sientra on 9 of the 14 factors compared between the two stocks.

Inogen vs. Invacare Stock

Invacare (NYSE:IVC) and Inogen (NASDAQ:INGN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, valuation, earnings, analyst recommendations, profitability and dividends.

Valuation & Earnings

This table compares Invacare and Inogen's top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Invacare	$927.96 million	0.35	$-53,330,000.00	($1.06)	-8.81
Inogen	$361.94 million	3.10	$20.95 million	$1.07	47.07

Inogen has lower revenue, but higher earnings than Invacare. Invacare is trading at a lower price-to-earnings ratio than Inogen, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Invacare has a beta of 0.94, meaning that its stock price is 6% less volatile than the S&P 500. Comparatively, Inogen has a beta of 1.05, meaning that its stock price is 5% more volatile than the S&P 500.

Institutional & Insider Ownership

96.7% of Invacare shares are owned by institutional investors. Comparatively, 95.1% of Inogen shares are owned by institutional investors. 3.2% of Invacare shares are owned by company insiders. Comparatively, 4.8% of Inogen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and target prices for Invacare and Inogen, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Invacare	0	0	2	0	3.00
Inogen	0	3	1	0	2.25

Invacare currently has a consensus price target of $14.00, indicating a potential upside of 51.02%. Inogen has a consensus price target of $63.00, indicating a potential upside of 22.35%. Given Invacare's stronger consensus rating and higher probable upside, equities analysts clearly believe Invacare is more favorable than Inogen.

Profitability

This table compares Invacare and Inogen's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Invacare	-4.87%	-8.76%	-3.07%
Inogen	-0.66%	0.21%	0.16%

Summary

Inogen beats Invacare on 8 of the 14 factors compared between the two stocks.

Inogen vs. Lakeland Industries Stock

Inogen (NASDAQ:INGN) and Lakeland Industries (NASDAQ:LAKE) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, risk, dividends and valuation.

Institutional & Insider Ownership

95.1% of Inogen shares are owned by institutional investors. Comparatively, 70.8% of Lakeland Industries shares are owned by institutional investors. 4.8% of Inogen shares are owned by insiders. Comparatively, 4.9% of Lakeland Industries shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Inogen and Lakeland Industries, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inogen	0	3	1	0	2.25
Lakeland Industries	0	0	3	0	3.00

Inogen currently has a consensus target price of $63.00, indicating a potential upside of 22.35%. Lakeland Industries has a consensus target price of $31.3333, indicating a potential downside of 4.33%. Given Inogen's higher probable upside, analysts clearly believe Inogen is more favorable than Lakeland Industries.

Profitability

This table compares Inogen and Lakeland Industries' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Inogen	-0.66%	0.21%	0.16%
Lakeland Industries	18.93%	28.75%	24.67%

Valuation and Earnings

This table compares Inogen and Lakeland Industries' revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inogen	$361.94 million	3.10	$20.95 million	$1.07	47.07
Lakeland Industries	$107.81 million	2.46	$3.28 million	$0.45	73.56

Inogen has higher revenue and earnings than Lakeland Industries. Inogen is trading at a lower price-to-earnings ratio than Lakeland Industries, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Inogen has a beta of 1.05, meaning that its stock price is 5% more volatile than the S&P 500. Comparatively, Lakeland Industries has a beta of 0.03, meaning that its stock price is 97% less volatile than the S&P 500.